Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report.

Abstract

Based on its ability to inhibit the tyrosine kinase activity of ABL, as well as the c-kit and the Platelet Derived Growth Factor Receptor tyrosine kinases, the spectrum of diseases that may respond to STI571 is increasing. A recently recognized subgroup of myeloproliferative disorders/myelodysplastic syndromes (MPD/MDS) has a t(5;12)(q33;p13) with the activation of the gene for PDGFBR which encodes a receptor tyrosine kinase. Here, we present the case of a patient, with MPD/MDS, and eosinophilia, carrying a translocation t(5;12)(q33;p13) who achieved a complete remission following treatment with STI571, 400 mg daily. At the time of writing he still remains in complete remission with an excellent performance status. There is clearly a need for further studies of STI 571in MPD/MDS with chromosomal translocations involving PDGFBR to confirm this promising initial result.

• Authors: V Pitini, C Arrigo, D Teti, G Barresi, M Righi, G Alo
• Journal: Haematologica (Haematologica) Vol. 88 Issue 5 Pg. ECR18 (May 2003) ISSN: 1592-8721 [Electronic] Italy
• PMID: 12745287 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Benzamides
• Enzyme Inhibitors
• Piperazines
• Pyrimidines
• Imatinib Mesylate
• Receptor, Platelet-Derived Growth Factor beta

Topics

• Aged
• Antineoplastic Agents (therapeutic use)
• Benzamides
• Enzyme Inhibitors (therapeutic use)
• Eosinophilia (diagnosis, drug therapy)
• Humans
• Imatinib Mesylate
• Leukemia, Myelomonocytic, Chronic (diagnosis, drug therapy)
• Male
• Myelodysplastic Syndromes (diagnosis, drug therapy)
• Myeloproliferative Disorders (diagnosis, drug therapy)
• Piperazines (therapeutic use)
• Pyrimidines (therapeutic use)
• Receptor, Platelet-Derived Growth Factor beta (antagonists & inhibitors, genetics)
• Translocation, Genetic